Cytos secures eleventh-hour reprieve with €37m from venBio-led syndicate
This article was originally published in Scrip
The Swiss immunotherapy firm Cytos Biotechnology has secured a financial lifeline from a syndicate of investors led by venBio and including Amgen, Abingworth and Aisling Capital. A €37 million debt and equity financing will recapitalise the company and provide funds to progress its lead programme, a vaccine for allergic asthma.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.